Evidence map›Paper›PMID 22180803›Full record

ArticlePLoS neglected tropical diseases2011

Dynamics of parasite clearance in cutaneous leishmaniasis patients treated with miltefosine.

Thomas P C Dorlo, Pieter P A M van Thiel, Gerard J Schoone, Ymkje Stienstra, Michèle van Vugt, Jos H Beijnen, Peter J de Vries

Open access · goldAbstract readCase Reports
In one paragraph

Article in PLoS neglected tropical diseases, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 3 pooled it
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 3 syntheses or guidelines pooled it, 34 citations in OpenAlex.

  1. Interventions for Old World cutaneous leishmaniasis.The Cochrane database of systematic reviews · 2017
    Pooled it
  2. Interventions for Old World cutaneous leishmaniasis.The Cochrane database of systematic reviews · 2017
    Pooled it
  3. Pooled it
  4. Trial
  5. Cutaneous leishmaniasis in Afghanistan.Transactions of the Royal Society of Tropical Medicine and Hygiene · 2025
    Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. An update on pharmacotherapy for leishmaniasis.Expert opinion on pharmacotherapy · 2015
    Review
  14. Article
  15. Article
  16. Review
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Thomas P C DorloDivision of Infectious Diseases, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands. t.p.dorlo@amc.nl
Pieter P A M van Thiel
Gerard J Schoone
Ymkje Stienstra
Michèle van Vugt
Jos H Beijnen
Peter J de Vries
Academic Medical Center · NLUniversity of Amsterdam · NLRoyal Tropical Institute · NLThe Netherlands Cancer Institute · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Parasite loads were quantified in repeated skin biopsies from lesions of 2 patients with Old-World cutaneous leishmaniasis (CL) caused by Leishmania major and L. infantum during and after treatment with miltefosine. Miltefosine induced a rapid therapeutic effect on both infections with an initial decline of parasites of ∼1 log/week for the L. major infection. These observations illustrate the usability of quantifying parasite loads in skin lesions as a pharmacodynamic measure and quantitative descriptor of drug effect for CL supporting clinical assessment.

Indexed as

Antiprotozoal AgentsFemaleHumansLeishmania infantumLeishmania majorLeishmaniasis, CutaneousMaleMiddle AgedParasite LoadPhosphorylcholineSkinAntiprotozoal AgentsmiltefosinePhosphorylcholine

Identifiers

PMID22180803
PMCPMC3236732
OpenAlexW2023543886

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.